Anlotinib
- Generic Name
- Anlotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22FN3O3
- CAS Number
- 1058156-90-3
- Unique Ingredient Identifier
- GKF8S4C432
- Background
Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.
- Indication
用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。
用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 528
- Registration Number
- NCT04523272
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-07-01
- Target Recruit Count
- 90
- Registration Number
- NCT04453423
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 332
- Registration Number
- NCT04405505
- Locations
- 🇨🇳
The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Chinese Academy of Medical Sciencesand Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Jihong Liu
- Target Recruit Count
- 40
- Registration Number
- NCT04376073
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-04-24
- Target Recruit Count
- 240
- Registration Number
- NCT04358562
- Locations
- 🇨🇳
The Second Afiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 315
- Registration Number
- NCT04325763
- Locations
- 🇨🇳
Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Yuebei People's Hospital, Shaoguan, Guangdong, China
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Hunan Province Tumor Hospital
- Target Recruit Count
- 1200
- Registration Number
- NCT04322617
- Locations
- 🇨🇳
Yongchang Zhang, Changsha, Hunan, China
Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 13
- Registration Number
- NCT04309136
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 138
- Registration Number
- NCT04291248
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital of The PLA Air Force Medical University, Xi'an, Shanxi, China
🇨🇳Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04273815
- Locations
- 🇨🇳
Jinling Hospital, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.